Lingyin Li, PhD
@lingyinli.bsky.social
Prof. at @stanford.edu & Core Investigator at @arcinstitute.org |
Uncovering drug targets in innate immunity and developing therapeutics for cancer and autoimmunity | Mother of 2 |
https://arcinstitute.org/labs/lilab
Uncovering drug targets in innate immunity and developing therapeutics for cancer and autoimmunity | Mother of 2 |
https://arcinstitute.org/labs/lilab
Stanford MSTP student Songnan Wang and I wrote a preview on Nan Yan's discovery of the immunotransmitter function of 2-5A in the dsRNA sensing. With two big fields emerging, we draw conceptual comparisons with the immunotransmitter cGAMP in the dsDNA sensing. authors.elsevier.com/a/1kuse3qNrU...
authors.elsevier.com
April 8, 2025 at 5:00 PM
Stanford MSTP student Songnan Wang and I wrote a preview on Nan Yan's discovery of the immunotransmitter function of 2-5A in the dsRNA sensing. With two big fields emerging, we draw conceptual comparisons with the immunotransmitter cGAMP in the dsDNA sensing. authors.elsevier.com/a/1kuse3qNrU...
At the AACR IO meeting in LA. Come say hi if you are here.
February 24, 2025 at 6:15 PM
At the AACR IO meeting in LA. Come say hi if you are here.
Reposted by Lingyin Li, PhD
Exciting new discovery from colleagues @stanfordmedicine.bsky.social, astrocyte metabolism compromised by amyloid and tau oligomers leading to insufficient support for neurons. Possible new target for treating AD.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indo...
www.science.org
November 26, 2024 at 5:31 PM
Exciting new discovery from colleagues @stanfordmedicine.bsky.social, astrocyte metabolism compromised by amyloid and tau oligomers leading to insufficient support for neurons. Possible new target for treating AD.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
What a great piece of news so many years in the making. Congratulations Profs Monjie and Mackall.
Congratulations Profs Monjie and Mackall and collaborators at Stanford Med, GD2 CAR-T shows efficacy in phase 1 brain cancer trial @stanfordpress.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas - Nature
We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of GD2-CART, followed by i...
www.nature.com
November 14, 2024 at 10:52 PM
What a great piece of news so many years in the making. Congratulations Profs Monjie and Mackall.